Reversible acylation of factor Xa as a potential therapy for hemophilia

Thrombosis Research
P H LinU Sinha

Abstract

Current therapies for treatment of hemophilia A involve infusion of factor VIII, but are ineffective for patients who develop inhibitory antibodies. We have previously proposed that bypassing the intrinsic pathway (VIIIa/IXa) with reversibly acylated factor Xa offers an improvement on existing therapies as it provides a time-dependent release of procoagulant activity without the addition of factors VIII or IX. The present study was designed to determine the effect of substituted 4-amidinophenyl benzoates on the acylation of factor Xa, as well as the subsequent deacylation rates of the resulting acyl Xa. A subset of this series of acyl Xa's were incorporated into the prothrombinase complex and recovery of catalytic activity was measured by activation of prothrombin to thrombin. Similarly, some acyl Xa's were also evaluated for their capacity to enhance clotting times of human plasma. Our study indicates that by choosing the appropriate acyl Xa, the time course of factor Xa regeneration can be modulated extensively. Animal studies will be required to show that the use of acyl Xa as a procoagulant agent is feasible in an in vivo system.

References

Sep 1, 1967·Biochemistry·T H Fife, J B Milstien
Aug 1, 1993·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·B G MacikH R Roberts
Jan 1, 1995·Advances in Experimental Medicine and Biology·C Hay, J N Lozier
Jan 1, 1996·Vox Sanguinis·G C White, H R Roberts

❮ Previous
Next ❯

Citations

Mar 25, 2000·Bioorganic & Medicinal Chemistry·E J Enyedy, I M Kovach
Oct 7, 2005·The Journal of Biological Chemistry·Virginie B Louvain-QuintardBernard F Le Bonniec

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.